Absci (ABSI) to Release Quarterly Earnings on Tuesday

Absci (NASDAQ:ABSI) is scheduled to be issuing its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Absci (NASDAQ:ABSI) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). Absci had a negative net margin of 2,838.89% and a negative return on equity of 44.24%. The business had revenue of $1.27 million during the quarter, compared to analyst estimates of $2.05 million. During the same quarter last year, the company posted ($0.27) earnings per share. On average, analysts expect Absci to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Absci Stock Performance

Shares of Absci stock opened at $4.00 on Tuesday. The stock has a market cap of $454.24 million, a price-to-earnings ratio of -4.30 and a beta of 2.18. Absci has a twelve month low of $1.18 and a twelve month high of $6.72. The company’s fifty day moving average is $4.01 and its 200 day moving average is $4.11. The company has a quick ratio of 6.49, a current ratio of 6.49 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

ABSI has been the topic of a number of recent analyst reports. Guggenheim started coverage on Absci in a research note on Wednesday, October 2nd. They issued a “buy” rating and a $10.00 price objective on the stock. KeyCorp dropped their price target on shares of Absci from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Absci in a research note on Thursday, August 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $8.67.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.